NCT06331806

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity: Clinical and Prognostic Implications

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: European Institute of Oncology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

Detailed description

The main aim of this interventional study is to evaluate biochemical and imaging markers of fibrosis in patients who had previously developed AIC during or after anthracycline-containing therapy. Anthracycline-induced cardiomyopathy (AIC) is define as a reduction in Left Ventricular Ejection Fraction (LVEF) \>10% units from baseline and below 50%, assessed by echocardiography, during or after anthracycline-containing therapy. All patients will undergo: * at time 0 * an echocardiogram with LVEF evaluation (biplane method) * a single blood sample. * at time 1 - a Cardiac Magnetic Resonance (RMC) with contrast agent (T1 mapping technique) (time 1 = within 72 hours from blood sample).

Conditions

• Cardiomyopathy Due to Drug

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Evaluation of myocardial fibrosis	echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent

Timeline

• Start date: 2018-02-22
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2024-03-26
• Last updated: 2024-06-24

Locations

1 site across 1 country: Italy